What is the role of angiotensin-receptor blockade in cardiovascular protection?

American Heart Journal

Volumn 152, Issue 5, 2006, Pages 859.e1-859.e8

  Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; LOSARTAN; RAMIPRIL; VALSARTAN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG EFFECT; DRUG MEGADOSE; EARLY INTERVENTION; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; EVALUATION; EVIDENCE BASED MEDICINE; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INFORMATION PROCESSING; KIDNEY FUNCTION; MEDIATOR; MEDICAL RESEARCH; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; RECEPTOR BLOCKING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SYMPTOMATOLOGY; TISSUE REPAIR;

EID: 33750303899     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.08.001     Document Type: Article

References (77)

1. Dzau V.J. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37 (2001) 1047-1052
2. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89 Suppl 2A (2002) 3A-10A
3. Dzau V.J., and Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift?. Circulation 89 (1994) 493-498
4. Givertz M.M. Manipulation of the renin-angiotensin system. Circulation 104 (2001) e14-e18
5. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
6. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al., for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
7. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 (1992) 685-691
8. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
9. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
10. Wright Jr. J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288 (2002) 2421-2431
11. Brenner B.M., Cooper E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
12. Niklason A., Hedner T., Niskanen L., et al., for the Captopril Prevention Project Study Group. Development of diabetes is retarded by ACE inhibition in hypertensive patients: a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens 22 (2004) 645-652
13. Devereux R.B., Dahlöf B., Gerdts E., et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) trial. Circulation 110 (2004) 1456-1462
14. Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 325 (1991) 966-967
15. Kannel W.B. Blood pressure as a cardiovascular risk factor. JAMA 275 (1996) 1571-1576
16. Ridker P.M., Glynn R.J., and Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97 (1998) 2007-2011
17. Haider A.W., Larson M.G., Franklin S.S., et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 138 (2003) 10-16
18. Lloyd-Jones D.M., Wilson P.W.F., Larson M.G., et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med 163 (2003) 1966-1972
19. Grundy S.M., Pasternak R., Greenland P., et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 34 (1999) 1348-1359
20. Jackson R., Lawes C.M.M., Milne R.J., et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 365 (2005) 434-441
21. De Backer G., Ambrosioni E., Borch-Johnsen K., et al., for the Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 24 (2003) 1601-1610
22. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363 (2004) 2022-2031
23. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360 (2002) 752-760
24. Verdecchia P., Reboldi G., Angeli F., et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43 (2004) 963-969
25. Yusuf S., Pfeffer M.A., Swedberg K., et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003) 777-781
26. Lee V.C., Rhew D.C., Dylan M., et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 141 (2004) 693-704
27. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329 (1993) 1456-1462
28. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
29. Parving H.-H., Lehnert H., Bröchner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
30. Karalliedde J., and Viberti G. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 20 (2006) 239-253
31. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
32. Lindholm L.H., Ibsen H., Borch-Johnsen K., et al. Risk of new-onset diabetes in the losartan endpoint reduction in hypertension study. J Hypertens 20 (2002) 1879-1886
33. Abuissa H., Jones P.G., Marso S.P., et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46 (2005) 821-826
34. Lonn E., Yusuf S., Dzavik V., et al. Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 103 (2001) 919-925
35. Lonn E., Shaikholeslami R., Yi Q., et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial. J Am Coll Cardiol 43 (2004) 2200-2206
36. Mathew J., Sleight P., Lonn E., et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104 (2001) 1615-1621
37. Wong M., Staszewsky L., Latini R., et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 40 (2002) 970-975
38. Olsen M.H., Wachtell K., Tuxen C., et al. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 23 (2005) 1083-1090
39. Latini R., Masson S., Anand I., et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106 (2002) 2454-2458
40. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000) 253-259
41. Pfeffer M.A., Swedberg K., Granger C.B., et al., for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
42. Cohn J.N., Hoke L., Whitwam W., et al. Screening for early detection of cardiovascular disease in asymptomatic individuals. Am Heart J 146 (2003) 679-685
43. Persson M., Carlberg B., Weinehall L., et al. Risk stratification by guidelines compared with risk assessment by risk equations applied to a MONICA sample. J Hypertens 21 (2003) 1089-1095
44. D'Agostino R.B., Grundy S., Sullivan L.M., et al., for the CHD Risk Prediction Group. Validation of the Framingham Coronary Heart Disease Prediction Scores: results of a multiple ethnic group investigation. JAMA 286 (2001) 180-187
45. Grey E., Bratelli C., Glasser S.P., et al. Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am J Hypertens 16 (2003) 265-269
46. Gibbons G.H., and Dzau V.J. The emerging concept of vascular remodeling. N Engl J Med 330 (1994) 1431-1438
47. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
48. Vita J.A., and Loscalzo J. Shouldering the risk factor burden: infection, atherosclerosis, and the vascular endothelium. Circulation 106 (2002) 164-166
49. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies, part I. Circulation 108 (2003) 1664-1672
50. Ridker P.M., Gaboury C.L., Conlin P.R., et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 87 (1993) 1969-1973
51. Vaughan D.E., Lazos S.A., and Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 95 (1995) 995-1001
52. Anderson T.J., Uehata A., Gerhard M.D., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26 (1995) 1235-1241
53. Clarkson P., Celermajer D.S., Powe A.J., et al. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation 96 (1997) 3378-3383
54. McVeigh G.E., Plumb R., and Hughes S. Vascular abnormalities in hypertension: cause, effect, or therapeutic target. Curr Hypertens Rep 6 (2004) 171-176
55. Duprez D.A., Kaiser D.R., Whitwam W., et al. Determinants of radial artery pulse wave analysis in asymptomatic individuals. Am J Hypertens 17 (2004) 647-653
56. Oliver J.J., and Webb D.J. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 23 (2003) 554-566
57. Boutouyrie P., Tropeano A.I., Asmar R., et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 39 (2002) 10-15
58. Simons P.C.G., Algra A., Bots M.L., et al., for the SMART Study Group. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation 100 (1999) 951-957
59. Blacher J., Guerin A.P., Pannier B., et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99 (1999) 2434-2439
60. Beltran A., McVeigh G., Morgan D., et al. Arterial compliance abnormalities in isolated systolic hypertension. Am J Hypertens 14 (2001) 1007-1011
61. Duprez D.A., de Buyzere M.L., de Backer T.L., et al. Relationship between arterial elasticity indices and carotid artery intima-media thickness. Am J Hypertens 13 (2000) 1226-1232
62. Barenbrock M., Hausberg M., Kosch M., et al. Flow-mediated vasodilation and distensibility in relation to intima-media thickness of large arteries in mild essential hypertension. Am J Hypertens 12 (1999) 973-979
63. Cohn J.N., Ferrari R., Sharpe N., and on behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling-concepts and clinical implications: a consensus paper from an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35 (2000) 569-582
64. Cohn J.N., Finkelstein S., McVeigh G., et al. Noninvasive pulse wave analysis for the early detection of vascular disease. Hypertension 26 (1995) 503-508
65. McDonagh T.A., Morrison C.E., Lawrence A., et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 350 (1997) 829-833
66. Rodeheffer R.J. Epidemiology and screening of asymptomatic left ventricular dysfunction. J Card Fail 8 Suppl (2002) S253-S257
67. Monahan K.D., Tanaka H., Dinenno F.A., et al. Central arterial compliance is associated with age- and habitual exercise-related differences in cardiovagal baroreflex sensitivity. Circulation 104 (2001) 1627-1632
68. Lim P.O., Shiels P., Anderson J., et al. Dundee step test: a simple method of measuring the blood pressure response to exercise. J Hum Hypertens 13 (1999) 521-525
69. Leung H., Wang J.J., Rochtchina E., et al. Impact of current and past blood pressure on retinal arteriolar diameter in an older population. J Hypertens 22 (2004) 1543-1549
70. Hyman B.N. Hypertensive retinopathy: the importance of ophthalmoscopy in the assessment of target-organ damage (TOD). Am J Hypertens 15 Suppl 1 (2002) 66A [Abstract P-97]
71. Crouse III J.R. Imaging atherosclerosis: state of the art. J Lipid Res 47 (2006) 1677-1699
72. Maisel A. B-type natriuretic peptide levels: a potential novel "white count" for congestive heart failure. J Card Fail 7 (2001) 183-193
73. Maisel A.S., Koon J., Krishnaswamy P., et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 141 (2001) 367-374
74. Borch-Johnsen K., Feldt-Rasmussen B., Strandgaard S., et al. Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19 (1999) 1992-1997
75. de Zeeuw D., Remuzzi G., Parving H.-H., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 (2004) 921-927
76. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
77. Campo C., Ruilope L.M., Segura J., et al. Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension. Blood Press 12 (2003) 277-283